This clinical trial is focused on studying the long-term safety and effectiveness of a medication called Povorcitinib for individuals with a skin condition known as Hidradenitis Suppurativa. Hidradenitis Suppurativa is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where skin rubs together. The study aims to understand how safe Povorcitinib is when used over an extended period.
Participants in the study will take Povorcitinib in the form of a tablet, which is taken orally. The study will last for up to 54 weeks, during which participants will be monitored for any side effects or changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substance. The study will help determine if Povorcitinib is a safe and effective treatment option for managing the symptoms of Hidradenitis Suppurativa.
Throughout the study, researchers will collect information on any adverse events, which are any unwanted effects that occur while taking the medication. They will also assess how well the medication works in reducing the symptoms of Hidradenitis Suppurativa, such as the number of lumps and tunnels under the skin. This information will contribute to understanding the potential benefits and risks of using Povorcitinib for this condition.
1joining the study
Participation begins after completing a previous study without safety concerns. Eligibility requires understanding and signing a consent form, compliance with previous study procedures, and agreement to use contraception.
2medication administration
The medication used in this study is Povorcitinib, administered in tablet form. The route of administration is oral. Specific dosage and frequency details are provided by the study team.
3monitoring and assessments
Regular visits are scheduled to monitor health and assess the effectiveness of the treatment. These assessments include checking for any adverse effects and measuring the reduction in symptoms of hidradenitis suppurativa.
4evaluation of treatment response
The study evaluates the proportion of participants experiencing adverse events and the effectiveness of the treatment in reducing symptoms. This includes measuring the reduction in abscesses and nodules.
5quality of life assessments
Participants complete questionnaires to assess the impact of the condition on daily life. These assessments help understand the treatment’s effect on quality of life.
6completion of the study
The study is estimated to end by January 2027. Participants will have a final assessment to evaluate the long-term safety and effectiveness of the treatment.
Who Can Join the Study?
Must be able to understand and willing to sign a written document agreeing to participate in the study.
Must have completed a 54-week treatment period in a previous related study without any safety issues, as determined by the study doctor.
Must have followed the rules and procedures of the previous study, as checked by the study doctor.
Must agree to use birth control methods as described in the study’s guidelines.
Must be willing and able to follow the study’s rules and procedures.
Who Cannot Join the Study?
Patients who have a different condition than Hidradenitis Suppurativa cannot participate. This is a skin condition that causes small, painful lumps under the skin.
Patients who are not within the specified age range cannot participate. The age range includes both children and adults.
Both males and females can participate, so gender is not a reason for exclusion.
Patients who are considered part of a vulnerable population may be excluded. This term refers to groups of people who might be at a higher risk of harm or exploitation, such as children, pregnant women, or those with certain disabilities.
Povorcitinib is a medication being studied for its long-term safety and effectiveness in treating moderate to severe hidradenitis suppurativa, a chronic skin condition. The trial aims to understand how well this medication works over an extended period and to monitor any potential side effects.
Hidradenitis Suppurativa – Hidradenitis Suppurativa is a chronic skin condition characterized by the formation of painful lumps under the skin, typically in areas where skin rubs together, such as the armpits, groin, and under the breasts. These lumps can become inflamed and may rupture, leading to the formation of abscesses and tunnels under the skin. Over time, the condition can cause scarring and the development of sinus tracts, which are channels that connect the lumps under the skin. The disease often progresses with periods of flare-ups and remission, where symptoms may temporarily improve. The exact cause of Hidradenitis Suppurativa is not fully understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Bulgaria 
Czechia 
Denmark 
France 
Germany 
Greece 
Italy 
Poland 
Spain 
The Netherlands